1. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease.
- Author
-
Locatelli F, Del Vecchio L, Esposito C, Gesualdo L, Grandaliano G, Ravera M, and Minutolo R
- Subjects
- Humans, Consensus, Hematinics therapeutic use, Italy, Prolyl-Hydroxylase Inhibitors therapeutic use, Societies, Medical, Renal Insufficiency, Chronic complications, Anemia drug therapy, Anemia etiology, Nephrology standards, Hypoxia-Inducible Factor-Proline Dioxygenases antagonists & inhibitors
- Abstract
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new drugs developed for the treatment of anemia associated with chronic kidney disease (CKD). This class of drugs stimulates endogenous erythropoietin production and, at the same time, improves iron absorption and mobilization of iron stores (less evident with daprodustat, vadadustat and enarodustat). Several studies have been published in the last few years showing that these agents are not inferior to standard therapy in correcting anemia associated with CKD. The efficacy of HIF-PHIs is coupled with a safety profile comparable to that of standard erythropoiesis stimulating agent (ESA) treatment. However, studies with HIF-PHIs were not long enough to definitively exclude the impact of new drugs on adverse events, such as cancer, death and possibly cardiovascular events, that usually occur after a long follow-up period. Kidney Disease: Improving Global Outcomes (KDIGO) recently reported the conclusions of the Controversies Conference on HIF-PHIs held in 2021. The goal of the present position paper endorsed by the Italian Society of Nephrology is to better adapt the conclusions of the latest KDIGO Conference on HIF-PHIs to the Italian context by reviewing the efficacy and safety of HIF-PHIs as well as their use in subpopulations of interest as emerged from more recent publications not discussed during the KDIGO Conference., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF